Steven Elms

Steven Elms

Vorsitzender bei ADMA BIOLOGICS, INC.

Vermögen: 701 553 $ am 31.05.2026

62 Jahre
Health Technology
Finance
Health Services

Profil

Steven Arnote Elms is currently Chairman at ADMA Biologics, Inc. since 2012.
He is an Independent Director at Marker Therapeutics, Inc. since 2019 and serves on the Board of Directors at Ajax Health LLC.
He is Director at Marker Cell Therapy, Inc. since 2019, Director at Ajax Health II LLC, Director at Treeline Biosciences, Inc., Managing Partner at Aisling Capital LLC since 2000, Managing Member at Aisling Capital Partners LLC, and Member-INVO Board at Northwestern University.
Former positions include Chairman at MAP Pharmaceuticals LLC from 2004 to 2011, Co-Chairman at LENSAR, Inc., Chairman at Adams Respiratory Therapeutics, Inc. from 2001 to 2006, Chairman at Oculex Pharmaceuticals, Inc., Chairman at Elevation Oncology, Inc. from 2020 to 2025, Director at Bioenvision, Inc. from 2002 to 2007, Director at Advion BioSciences, Inc., Director at Avera Pharmaceuticals, Inc. from 2004 to 2013, Director at Ambit Biosciences Corp.
from 2001 to 2014, Independent Director at TRIA Beauty, Inc. from 2012 to 2013, Director at CeNeRx BioPharma, Inc., Director at NextWave Pharmaceuticals, Inc., Director at Earlens Corp., Director at Advion, Inc., Director at Novazyme Pharmaceuticals, Inc., Director at Medical Knowledge Group LLC, Director at Scerene Healthcare, Inc., Director at Archimica Cooperatief UA, Independent Non-Executive Director at Pernix Therapeutics Holdings, Inc. from 2011 to 2016, Independent Director at Zosano Pharma Corp.
from 2018 to 2022, Independent Director at Loxo Oncology, Inc. from 2013 to 2019, Independent Director at Cidara Therapeutics, Inc. from 2014 to 2015, Principal at Hambrecht & Quist Group, Consultant at Wilkerson Group, Principal at Marion Laboratories, and Principal-Life Sciences Investment Banking Group at Hambrecht & Quist.
Education includes undergraduate studies at Stanford University and an MBA from Kellogg School of Management.

Bekannte Unternehmensbeteiligungen

UnternehmenDatumAnzahl der AktienBewertungDatum der Bewertung
31.03.2026 87 330 ( 0,04 % ) 696 893 $ 31.05.2026
01.03.2026 2 968 ( 0,02 % ) 4 660 $ 31.05.2026

Aktive Positionen von Steven Elms

UnternehmenPositionBeginn
ADMA BIOLOGICS, INC. Vorsitzender 30.03.2012
MARKER THERAPEUTICS, INC. Direktor/Vorstandsmitglied 06.08.2019
Aisling Capital Partners LLC
Corporate Officer/Principal -
Direktor/Vorstandsmitglied 06.08.2019
Corporate Officer/Principal -
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied -
Direktor/Vorstandsmitglied -
Private Equity Investor 01.07.2000

Ehemalige bekannte Positionen von Steven Elms

UnternehmenPositionEnde
░░░░ ░░░░ ░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Sehen Sie sich die Erfahrung von Steven Elms im Detail an

Ausbildung von Steven Elms

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Beziehungen

59

Beziehungen ersten Grades

37

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Unternehmensverbindungen

Private Unternehmen37

Finance

Health Services

Health Technology

Commercial Services

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Aisling Capital Partners LLC

Health Technology

Health Technology

Consumer Services

Commercial Services

Health Services

Health Technology

Consumer Services

Distribution Services

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Hambrecht & Quist

Finance

Commercial Services

Finance

Health Technology

Health Technology

  1. Börse
  2. Insiders
  3. Steven Elms
- 40 %: Die besten Tools - exklusiv für Abonnenten - um schon heute die Top-Anlagechancen von morgen zu erkennen!
T
:
:
PROFITIEREN SIE JETZT